Regeneron, Avalanche Biotechnologies to collaborate on gene therapy products

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration agreement centered on the development of novel ophthalmic genetic therapy products, according to a press release. Avalanche’s AVA-101 is currently undergoing a phase 2a trial for wet age-related macular degeneration. Avalanche also has a proprietary adeno-associated virus-based gene therapy discovery and development technology called the Ocular BioFactory platform, according to the release.

Full Story →